IndustryCompany release

Certara Q3 revenue rises 4% to $94.9M as software grows 11%

🇺🇸 Certara, Inc. (CERT) · Thu 05 Nov 2026

The model-informed drug development company narrowed its 2026 revenue growth outlook to 2% to 3% and appointed Grant Peterson as Chief Product Officer.

Certara (Nasdaq: CERT), which provides model-informed drug development software and services, reported third-quarter 2026 results on 5 November. Revenue from continuing operations came to $94.9M, up 4%.

Software was the stronger segment, with revenue up 11% to $48.8M. Services revenue moved the other way, falling 2%.

The company narrowed its net loss to $3.6M and ended the period with cash of $214.9M. The source summary does not give comparative figures for the prior year's loss or other balance sheet items.

Certara also narrowed its 2026 revenue growth guidance to a range of 2% to 3%. Separately, it named Grant Peterson Chief Product Officer, effective 2 November.

What it means for your team

  • Software, rather than services, is driving Certara's growth, which may be relevant to teams weighing modelling tools against outsourced modelling support.
  • A narrowed full-year growth range of 2% to 3% signals modest expansion; teams reliant on Certara offerings should watch for further detail on product direction.
  • The new Chief Product Officer appointment may shape the company's product roadmap, though no specifics were provided.

Company's press release (SEC filing): Certara, Inc. ↗

Article written by VigiEye from the official source (Certara, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →